Cell therapy in heart failure has been tested in one of the largest trials in the field.
Cardiovascular applications of cell therapy have been studied more rigorously than almost any other area, including a large randomized, sham-controlled phase 3 trial in chronic heart failure. The results are genuinely interesting and genuinely mixed, and both halves belong on this page.
Here is what that research found, what it did not, and why cardiology is a category where coordination with your existing care is non-negotiable.
Aurenza does not claim that regenerative medicine treats, cures, or reverses any cardiovascular condition.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What the Research Shows
Cardiovascular applications carry the largest single randomized trial in this entire field, and the way we handle its results is a fair test of whether any provider deserves your trust.
The DREAM-HF trial, published in the Journal of the American College of Cardiology (2023), was a phase 3, multinational, randomized, double-blind, sham-controlled study of a single transendocardial administration of mesenchymal precursor cells in chronic heart failure with reduced ejection fraction, on top of guideline-directed therapy, in 565 intention-to-treat patients. The investigators reported a long-term 58% reduction in the prespecified composite of heart attack or stroke in treated patients, and the accompanying JACC editorial walks through the trial's scale and rigor. The mechanism is described in the trial's design publication in Circulation Research: polarizing proinflammatory macrophages in the heart toward an anti-inflammatory state, inhibiting adverse remodeling, and improving endothelial function, with treatment effects most apparent in patients with evidence of inflammation.
The Honest Line
Now the other half, which most marketing pages omit and we will not. DREAM-HF did not meet its primary endpoint of reducing recurrent heart failure hospitalizations, and the broader composite including cardiovascular death showed a 27% risk reduction in post hoc analysis that did not reach statistical significance. No cell therapy is approved anywhere for chronic heart failure. What exists is a large, rigorous trial with a genuine signal on heart attack and stroke, a missed primary endpoint, and open questions awaiting confirmation. No study shows a guarantee it works every time, or that it will work for you, and nothing here is a reason to change cardiac care built on some of the most effective medications in all of medicine.
Why This Is Exactly Where a Candidacy Review Comes In
This is also the one category where a review's most important power is the power to say no: uncontrolled disease, recent events, and unstable rhythms end a candidacy conversation rather than shape it, and a review that cannot tell you no is not worth having. Every trial above produced its results in selected patients who met specific criteria. That is the gap between "documented in research" and "right for you," and it is the gap a candidacy review exists to close. Before anything is recommended, your bloodwork, biomarkers, imaging, and history are reviewed by a physician panel to establish whether you are actually in the population the research describes. If the picture supports moving forward, you will know exactly why. If it does not, you will be told that, plainly. That is where to start.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What Your Candidacy Review Covers
What to Ask Any Provider
Which trial data are you relying on, and how does my heart failure type compare to the patients studied? Is my cardiologist part of this conversation? What exactly is being administered, by what route, and with what monitoring? What findings in my workup would stop this from going forward? What are the realistic possibilities, including no change?
The Honest Limits
Individual results cannot be predicted or guaranteed. No cell therapy is FDA approved for heart failure or other chronic cardiovascular conditions, and any procedure takes place in Mexico under COFEPRIS regulation. Never change cardiac medications except under your cardiologist's direction, and seek emergency care for chest pain, syncope, or new shortness of breath.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
Free consultation with a care consultant, many of whom are registered nurses. No sales reps. No receptionist.